Test Price
2,800 AED✅ Home Collection Available
MFN2 Gene CMT2A2 Next‑Generation Sequencing (NGS) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Ultra‑High‑Resolution Genetic Test for Charcot‑Marie‑Tooth Disease Type 2A2
DNA Labs UAE offers an advanced NGS‑based analysis of the MFN2 gene to detect pathogenic variants causing CMT2A2. The test delivers 99.9% diagnostic sensitivity across the entire coding region, enabling precise molecular confirmation for targeted family screening and personalised neurological management. Our DHA‑licensed facility (License 1143) ensures full compliance with UAE data protection and healthcare technology regulations. VIP mobile phlebotomy and temperature‑controlled cold‑chain home collection are available daily from 8 AM to 11 PM, backed by post‑result teleconsultation with a Consultant Medical Genetics specialist.
Test Overview & Methodology
The MFN2 gene test employs deep Next‑Generation Sequencing to achieve 100% coverage of the coding region and splice sites, detecting single nucleotide variants and small indels with analytical sensitivity exceeding 99.9%. This approach surpasses traditional Sanger sequencing by identifying low‑frequency mosaic variants and enabling simultaneous multi‑exon analysis.
| Feature | Our MFN2 NGS Test | Closest Alternative (PCR/Sanger Panel) |
|---|---|---|
| Methodology | Deep Next‑Generation Sequencing (100% coding region coverage) | Sanger sequencing of selected exons |
| Turnaround Time | 14‑21 working days (expedited available) | 4‑6 weeks |
| Regulatory Status | DHA Licensed, ISO 9001:2015, ICD‑10/LOINC compliant | Variable; often lacks UAE‑specific accreditation |
| Sample Type | Whole blood / Extracted DNA / FTA Card | Blood only |
| Privacy | UAE PDPL compliant; data stored in‑country | Often stored offshore |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant Medical Genetics specialist, I recognise the profound importance of a definitive molecular diagnosis for families affected by CMT2A2. The NGS test provides unprecedented sensitivity; however, the genetic result must be correlated with detailed clinical findings, nerve conduction studies, and family history. I urge patients to use this test as a tool for personalised management, not as a standalone answer.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
⚠️ Important Medication Notice
Do not discontinue or adjust any prescribed medication without direct consultation with your treating physician. This genetic test does not replace clinical monitoring or pharmacological management of neurological symptoms.
Exclusion Criteria & Emergency Red Flags
- Severe, uncontrolled bleeding diathesis or ongoing anticoagulant therapy without medical clearance (venipuncture risk).
- Inability to provide informed consent or lack of a legal guardian (mandatory for minors under Federal Decree‑Law No. 4 of 2016 on Medical Liability).
- Known allergy to latex or antiseptic products used in phlebotomy (alternative kit available on request).
- Acute febrile illness or systemic infection – postpone testing until recovered.
- If you experience sudden worsening of neuropathy, muscle atrophy, or respiratory difficulty, seek emergency care immediately; your genetic testing appointment should not delay acute evaluation.
Patient FAQ & Clinical Guidance
1. What is the MFN2 CMT2A2 genetic test used for?
This test identifies pathogenic variants in the MFN2 gene to confirm a clinical suspicion of Charcot‑Marie‑Tooth disease type 2A2, enabling targeted family screening and early neurological management. It detects DNA mutations causing inherited axonal neuropathy with 99.9% sensitivity using NGS technology.
2. How accurate is the NGS methodology compared to traditional tests?
Next‑Generation Sequencing delivers greater than 99.9% analytical sensitivity and specificity for single nucleotide variants and small indels, far exceeding older Sanger methods. It analyses the entire MFN2 coding region, detecting even low‑frequency variants missed by conventional panels.
3. What is the test price in AED and is it covered by insurance?
The total cost is AED 2,800, including home‑based specimen collection, cold‑chain logistics, and a post‑test teleconsultation. We verify insurance eligibility via WhatsApp and facilitate direct billing with major UAE medical networks.
4. How should I prepare for the blood collection?
No special preparation is required. A trained phlebotomist will visit your home between 8 AM and 11 PM. Ensure you are well‑hydrated and inform the phlebotomist of any bleeding disorders or anticoagulant use. A consent form will be reviewed and signed prior to collection.
5. When will I receive my results and how are they delivered?
Results are available within 14–21 working days. You will receive a secure digital report via email or the patient portal, followed by a teleconsultation with our genetics specialist to interpret the findings and discuss next steps.
UAE Regulatory & Data Privacy Adherence
Compliance Framework
This genetic testing service operates under DHA Facility License 1143 and adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient data handling, and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for health information governance. Clinical safety and patient consent are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. All genetic data is processed and stored exclusively within the UAE. Pre‑test genetic counselling is provided to ensure informed consent.
Clinical & Logistical Metadata
| Test Name | MFN2 Gene CMT2A2 Next‑Generation Sequencing (NGS) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 14–21 working days (expedited available) |
| Sample Type / Matrix | Whole blood, Extracted DNA, or FTA Card – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily 8 AM to 11 PM |
| Methodology Used | Next‑Generation Sequencing (NGS) – full coding region and splice site analysis |
| ICD-10-CM Code | G60.0 (Hereditary motor and sensory neuropathy) |
| LOINC Code | 94122-5 (MFN2 gene mutation analysis in Blood or Tissue by Molecular genetics method) |
| DHA Facility License & Laboratory Address | License 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians